espi gpw GENOMTEC S.A. 2023-10-20 09:33

Positive evaluation by PARP of the Company's application for funding under the European Funds for Modern Economy program.

The Management Board of Genomtec S.A. [Company, Genomtec] announces that on October 19, 2023, it became aware that the Polish Agency for Enterprise Development [PARP] has made available the results of the evaluation of the application submitted by the Company within the framework of the call implemented under the program European Funds for Modern Economy [Action Path SMART FENG.01.01-IP.02-001/23/2023] for the project entitled: "Development of technology and automated system for mutation detection in the field of clinical oncology based on lab-on-chip solution and isothermal nucleic acid amplification techniques" [Project]. The application was evaluated positively by PARP. The recommended amount of funding for the Project is about PLN 21.6 million with a total project budget of about PLN 40 million.

The subject of the Project is the development of technology and an automated system for mutation detection in the field of clinical oncology based on lab-on-chip solution and isothermal nucleic acid amplification techniques. The project includes three modules" R&D Work, Digitization and Internationalization.

The R&D work will include laboratory work on technology for detection of mutations in the field of oncology using microfluidic cards allowing diagnosis and enabling molecularly targeted cancer therapy. In the course of further work, the technology will be developed using a dedicated analyzer and a clinical trial will be conducted.

As part of the Digitization module, an investment will be made in tools to enable more efficient implementation of R&D work. As part of the Internationalization module, participation in a number of foreign trade fairs and protection of Genomtec S.A.'s intellectual property is planned.The project will be implemented in the period from January 2024 to June 2027.